<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29370829</article-id><article-id pub-id-type="pmc">5785898</article-id><article-id pub-id-type="publisher-id">2468</article-id><article-id pub-id-type="doi">10.1186/s13063-018-2468-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Text4Heart II – improving medication adherence in people with heart disease: a study protocol for a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Maddison</surname><given-names>Ralph</given-names></name><address><email>ralph.maddison@deakin.edu.au</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Stewart</surname><given-names>Ralph</given-names></name><address><email>RStewart@adhb.govt.nz</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Doughty</surname><given-names>Rob</given-names></name><address><email>r.doughty@auckland.ac.nz</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Scott</surname><given-names>Tony</given-names></name><address><email>tony.scott@waitematadhb.govt.nz</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kerr</surname><given-names>Andrew</given-names></name><address><email>a.kerr@auckland.ac.nz</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Benatar</surname><given-names>Jocelyne</given-names></name><address><email>JBenatar@adhb.govt.nz</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Whittaker</surname><given-names>Robyn</given-names></name><address><email>r.whitakker@auckland.ac.nz</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Rawstorn</surname><given-names>Jonathan C.</given-names></name><address><email>jonathan.rawstorn@deakin.edu.au</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rolleston</surname><given-names>Anna</given-names></name><address><email>anna@thecentreforhealth.co.nz</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Yannan</given-names></name><address><email>y.jang@auckland.ac.nz</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Estabrooks</surname><given-names>Paul</given-names></name><address><email>paul.estabrooks@unmc.edu</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Sullivan</surname><given-names>Rachel Karen</given-names></name><address><email>rachel.sullivan@auckland.ac.nz</email></address><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Bartley</surname><given-names>Hannah</given-names></name><address><email>h.bartley@auckland.ac.nz</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Pfaeffli Dale</surname><given-names>Leila</given-names></name><address><email>leila.dale@ubc.ca</email></address><xref ref-type="aff" rid="Aff10">10</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0526 7079</institution-id><institution-id institution-id-type="GRID">grid.1021.2</institution-id><institution>Institute for Physical Activity and Nutrition, Deakin University, </institution></institution-wrap>Geelong, VIC Australia </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0042 379X</institution-id><institution-id institution-id-type="GRID">grid.414057.3</institution-id><institution>Department of Cardiology, </institution><institution>Auckland District Health Board, </institution></institution-wrap>Auckland, New Zealand </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0372 3343</institution-id><institution-id institution-id-type="GRID">grid.9654.e</institution-id><institution>Heart Health Research Group, Department of Medicine, </institution><institution>University of Auckland, </institution></institution-wrap>Auckland, New Zealand </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9566 8206</institution-id><institution-id institution-id-type="GRID">grid.416904.e</institution-id><institution>Department of Cardiology, </institution><institution>Waitemata District Health Board, </institution></institution-wrap>Auckland, New Zealand </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0372 3343</institution-id><institution-id institution-id-type="GRID">grid.9654.e</institution-id><institution>Epidemiology and Biostatistics, </institution><institution>University of Auckland, </institution></institution-wrap>Auckland, New Zealand </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0372 3343</institution-id><institution-id institution-id-type="GRID">grid.9654.e</institution-id><institution>National Institute for Health Innovation, School of Population Health, University of Auckland, </institution></institution-wrap>Auckland, New Zealand </aff><aff id="Aff7"><label>7</label>The Centre for Health, Tauranga, New Zealand </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0775 5412</institution-id><institution-id institution-id-type="GRID">grid.266815.e</institution-id><institution>Department of Health Promotion, Social and Behavioral Health, </institution><institution>University of Nebraska Medical Centre, </institution></institution-wrap>Omaha, NE USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0372 3343</institution-id><institution-id institution-id-type="GRID">grid.9654.e</institution-id><institution>Department of Exercise Sciences, </institution><institution>Faculty of Science, University of Auckland, </institution></institution-wrap>Auckland, New Zealand </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2288 9830</institution-id><institution-id institution-id-type="GRID">grid.17091.3e</institution-id><institution>School of Kinesiology, University of British Columbia, </institution></institution-wrap>Vancouver, BC Canada </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>1</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>1</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>19</volume><elocation-id>70</elocation-id><history><date date-type="received"><day>27</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>11</day><month>1</month><year>2018</year></date></history><permissions><copyright-statement>© The Author(s). 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><offsets xml_i="8880" xml_f="8890" txt_i="11" txt_f="21">Background</offsets></title><p id="Par1"><offsets xml_i="8911" xml_f="9777" txt_i="22" txt_f="888">Cardiac rehabilitation (CR) is an essential component of contemporary management for patients with coronary heart disease, including following an acute coronary syndrome (ACS). CR typically involves education and support to assist people following an ACS to make lifestyle changes and prevent subsequent events. Despite its benefits, uptake and participation in tradition CR programs is low. The use of mobile technologies (mHealth) offers the potential to improve reach, access, and delivery of CR support. We aim to determine the effectiveness and cost-effectiveness of a text-messaging intervention (Text4Heart II) to improve adherence to medication and lifestyle change in addition to usual care in people following an ACS. A second aim is to use the RE-AIM framework to inform the potential implementation of Text4Heart II within health services in New Zealand.</offsets></p></sec><sec><title><offsets xml_i="9799" xml_f="9806" txt_i="890" txt_f="897">Methods</offsets></title><p id="Par3"><offsets xml_i="9827" xml_f="10944" txt_i="898" txt_f="2015">Text4Heart II is a two-arm, parallel, superiority randomized controlled trial conducted in two large metropolitan hospitals in Auckland, New Zealand. Three hundred and thirty participants will be randomized to either a 24-week theory- and evidence-based personalized text message program to support self-management in addition to usual CR, or usual CR alone (control). Outcomes are assessed at 6 and 12 months. The primary outcome is the proportion of participants adhering to medication at 6 months as measured by dispensed records. Secondary outcomes include medication adherence at 12 months, the proportion of participants adhering to self-reported healthy behaviors (physical activity, fruit and vegetable consumption, moderating alcohol intake and smoking status) measured using a composite health behavior score, self-reported medication adherence, cardiovascular risk factors (lipids, blood pressure), readmissions and related hospital events at 6 and 12 months. A cost-effectiveness analysis will also be conducted. Using the RE-AIM framework, we will determine uptake and sustainability of the intervention.</offsets></p></sec><sec><title><offsets xml_i="10966" xml_f="10976" txt_i="2017" txt_f="2027">Discussion</offsets></title><p id="Par4"><offsets xml_i="10997" xml_f="11616" txt_i="2028" txt_f="2647">The Text4Heart II trial will determine the effectiveness of a text-messaging intervention to improve adherence to medication and lifestyle behaviors at both 6 and 12 months. Using the RE-AIM framework this trial will provide much needed data and insight into the potential implementation of Text4Heart II. This trial addresses many limitations/criticisms of previous mHealth trials; it builds on our Text4Heart pilot trial, it is adequately powered, has sufficient duration to elicit behavior change, and the follow-up assessments (6 and 12 months) are long enough to determine the sustained effect of the intervention.</offsets></p></sec><sec><title><offsets xml_i="11638" xml_f="11656" txt_i="2649" txt_f="2667">Trial registration</offsets></title><p id="Par5"><offsets xml_i="11677" xml_f="11730" txt_i="2668" txt_f="2721">Australian New Zealand Clinical Trials Registry, ID: </offsets><ext-link ext-link-type="uri" xlink:href="http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=370398"><offsets xml_i="11844" xml_f="11863" txt_i="2721" txt_f="2740">ACTRN12616000422426</offsets></ext-link><offsets xml_i="11874" xml_f="11920" txt_i="2740" txt_f="2786">. Registered retrospectively on 1 April 2016. </offsets></p></sec><sec><title><offsets xml_i="11942" xml_f="11975" txt_i="2788" txt_f="2821">Electronic supplementary material</offsets></title><p><offsets xml_i="11986" xml_f="12121" txt_i="2822" txt_f="2957">The online version of this article (10.1186/s13063-018-2468-z) contains supplementary material, which is available to authorized users.</offsets></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cardiovascular disease</kwd><kwd>Self-management</kwd><kwd>Text messaging</kwd><kwd>Risk factors</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001505</institution-id><institution>Health Research Council of New Zealand</institution></institution-wrap></funding-source><award-id>15/667</award-id><principal-award-recipient><name><surname>Maddison</surname><given-names>Ralph</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001516</institution-id><institution>National Heart Foundation of New Zealand</institution></institution-wrap></funding-source><award-id>1684</award-id><principal-award-recipient><name><surname>Maddison</surname><given-names>Ralph</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title><offsets xml_i="13386" xml_f="13396" txt_i="2966" txt_f="2976">Background</offsets></title><p id="Par20"><offsets xml_i="13418" xml_f="13557" txt_i="2977" txt_f="3116">Cardiovascular diseases (CVD) are the leading causes of premature death and disability worldwide, accounting for 30% of all global deaths [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="13589" xml_f="13590" txt_i="3116" txt_f="3117">1</offsets></xref><offsets xml_i="13597" xml_f="13815" txt_i="3117" txt_f="3335">]. By 2030, almost 23.6 million people will die from CVD, mainly coronary heart disease (CHD), and the total number of disability-adjusted life years attributable to CVD is expected to reach approximately 204 million [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="13847" xml_f="13848" txt_i="3335" txt_f="3336">1</offsets></xref><offsets xml_i="13855" xml_f="14002" txt_i="3336" txt_f="3483">]. People with CVD are more likely to develop future cardiac events such as unstable angina, myocardial infarction (MI), and sudden cardiac death [</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="14034" xml_f="14035" txt_i="3483" txt_f="3484">2</offsets></xref><offsets xml_i="14042" xml_f="14165" txt_i="3484" txt_f="3607">]. This places a huge burden on healthcare systems, with the US spending US$444 billion on CVD-related treatments in 2010 [</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="14197" xml_f="14198" txt_i="3607" txt_f="3608">3</offsets></xref><offsets xml_i="14205" xml_f="14207" txt_i="3608" txt_f="3610">].</offsets></p><p id="Par21"><offsets xml_i="14225" xml_f="14349" txt_i="3611" txt_f="3735">Improved diagnosis, treatment, and management have substantially reduced the mortality rate of individuals living with CHD [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="14381" xml_f="14382" txt_i="3735" txt_f="3736">4</offsets></xref><offsets xml_i="14389" xml_f="14391" txt_i="3736" txt_f="3738">, </offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="14423" xml_f="14424" txt_i="3738" txt_f="3739">5</offsets></xref><offsets xml_i="14431" xml_f="14546" txt_i="3739" txt_f="3854">]; however, those who have experienced an MI have a 20–40% risk of a recurrent event or death in the next 5 years [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="14578" xml_f="14579" txt_i="3854" txt_f="3855">4</offsets></xref><offsets xml_i="14586" xml_f="14588" txt_i="3855" txt_f="3857">, </offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="14620" xml_f="14621" txt_i="3857" txt_f="3858">5</offsets></xref><offsets xml_i="14628" xml_f="14782" txt_i="3858" txt_f="4012">]. Approximately 80% of CHD is caused by modifiable risk factors including physical inactivity, smoking, unhealthy diet, and harmful alcohol consumption [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="14814" xml_f="14815" txt_i="4012" txt_f="4013">6</offsets></xref><offsets xml_i="14822" xml_f="15207" txt_i="4013" txt_f="4398">], and effective evidence-based secondary prevention treatments—such as implementing lifestyle changes and adhering to prescribed medication regimens (self-management)—can aid recovery and reduce recurrent cardiac events. Improvements in lipids, systolic blood pressure, smoking prevalence, and physical activity account for an estimated 47% of the total improvement in case fatality [</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="15239" xml_f="15240" txt_i="4398" txt_f="4399">5</offsets></xref><offsets xml_i="15247" xml_f="15249" txt_i="4399" txt_f="4401">].</offsets></p><sec id="Sec2"><title><offsets xml_i="15275" xml_f="15292" txt_i="4402" txt_f="4419">Management of CHD</offsets></title><p id="Par22"><offsets xml_i="15314" xml_f="16000" txt_i="4420" txt_f="5106">Acute coronary syndrome (ACS) encompasses unstable angina, and MI. Following diagnosis of an ACS, patients should receive a range of evidence-based preventive treatments that include appropriate clinical follow-up, as well as referral to programs that provide education and support self-management for the secondary prevention of disease—commonly known as cardiac rehabilitation (CR). A core focus of CR is to encourage people to make healthy lifestyle changes to reduce subsequent cardiac events. Lifestyle behavior changes include regular physical activity, eating a healthy diet, stopping smoking, reducing harmful alcohol intake, and taking medications as per a prescribed regimen [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="16032" xml_f="16033" txt_i="5106" txt_f="5107">7</offsets></xref><offsets xml_i="16040" xml_f="16137" txt_i="5107" txt_f="5204">]. Empowering self-management is critical for people with an ACS to maximize treatment benefits [</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="16169" xml_f="16170" txt_i="5204" txt_f="5205">8</offsets></xref><offsets xml_i="16177" xml_f="16179" txt_i="5205" txt_f="5207">].</offsets></p><p id="Par23"><offsets xml_i="16197" xml_f="16356" txt_i="5208" txt_f="5367">CR is an essential part of contemporary management for people with an ACS. It has been shown to reduce cardiovascular deaths and hospital readmissions by 25% [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="16388" xml_f="16389" txt_i="5367" txt_f="5368">7</offsets></xref><offsets xml_i="16396" xml_f="16448" txt_i="5368" txt_f="5420">], and is cost-effective for those who participate [</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="16480" xml_f="16481" txt_i="5420" txt_f="5421">9</offsets></xref><offsets xml_i="16488" xml_f="16521" txt_i="5421" txt_f="5454">]. A Cochrane systematic review [</offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="16554" xml_f="16556" txt_i="5454" txt_f="5456">10</offsets></xref><offsets xml_i="16563" xml_f="16909" txt_i="5456" txt_f="5802">] of CR reported a statistically significant reduction in cardiovascular mortality of 26% (odds ratio (OR) 0.74, 95% CI 0.57 to 0.96) and a reduction in all-cause mortality of 13% (OR 0.87, 95% confidence interval (CI) 0.71 to 1.05). This magnitude of effect is consistent with a review of cohort studies and randomized controlled trials (RCTs) [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="16942" xml_f="16944" txt_i="5802" txt_f="5804">11</offsets></xref><offsets xml_i="16951" xml_f="16953" txt_i="5804" txt_f="5806">].</offsets></p><p id="Par24"><offsets xml_i="16971" xml_f="17074" txt_i="5807" txt_f="5910">Despite these benefits, CR participation is inadequate in all countries in which it has been assessed [</offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="17107" xml_f="17109" txt_i="5910" txt_f="5912">12</offsets></xref><offsets xml_i="17116" xml_f="17311" txt_i="5912" txt_f="6107">]. Low levels of patient participation and completion (14–43% after MI) have been reported in Australia, France, the United Kingdom, and New Zealand with high levels of dropout after enrollment [</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="17344" xml_f="17346" txt_i="6107" txt_f="6109">13</offsets></xref><offsets xml_i="17353" xml_f="17354" txt_i="6109" txt_f="6110">–</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="17387" xml_f="17389" txt_i="6110" txt_f="6112">17</offsets></xref><offsets xml_i="17396" xml_f="17488" txt_i="6112" txt_f="6204">]. Lack of completion reduces the benefits of CR, such as improvements in CVD risk factors [</offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="17521" xml_f="17523" txt_i="6204" txt_f="6206">18</offsets></xref><offsets xml_i="17530" xml_f="17764" txt_i="6206" txt_f="6440">]. Patient-oriented, medical, and healthcare system factors associated with suboptimal participation include availability, affordability and accessibility of a program, as well as work/domestic commitments and psychological barriers [</offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="17797" xml_f="17799" txt_i="6440" txt_f="6442">19</offsets></xref><offsets xml_i="17806" xml_f="17808" txt_i="6442" txt_f="6444">, </offsets><xref ref-type="bibr" rid="CR20"><offsets xml_i="17841" xml_f="17843" txt_i="6444" txt_f="6446">20</offsets></xref><offsets xml_i="17850" xml_f="18069" txt_i="6446" txt_f="6665">]. Current CR delivery approaches do not suit all people and new models are needed to improve the uptake and completion of CR. A range of options should be available for people according to their preferences and needs [</offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="18102" xml_f="18104" txt_i="6665" txt_f="6667">21</offsets></xref><offsets xml_i="18111" xml_f="18113" txt_i="6667" txt_f="6669">].</offsets></p></sec><sec id="Sec3"><title><offsets xml_i="18145" xml_f="18186" txt_i="6671" txt_f="6712">New approaches to enhance self-management</offsets></title><p id="Par25"><offsets xml_i="18208" xml_f="18472" txt_i="6713" txt_f="6977">A recent systematic review of alternative models of care found multifactorial individualized telehealth and community- or home-based CR were effective alternatives as they have produced similar reductions in CVD risk factors compared with hospital-based programs [</offsets><xref ref-type="bibr" rid="CR22"><offsets xml_i="18505" xml_f="18507" txt_i="6977" txt_f="6979">22</offsets></xref><offsets xml_i="18514" xml_f="18575" txt_i="6979" txt_f="7040">]. This echoes findings from other reviews of home-based CR [</offsets><xref ref-type="bibr" rid="CR23"><offsets xml_i="18608" xml_f="18610" txt_i="7040" txt_f="7042">23</offsets></xref><offsets xml_i="18617" xml_f="18635" txt_i="7042" txt_f="7060">] and telehealth [</offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="18668" xml_f="18670" txt_i="7060" txt_f="7062">24</offsets></xref><offsets xml_i="18677" xml_f="19241" txt_i="7062" txt_f="7626">]. There is a paucity of research describing the effectiveness of alternative models of CR in rural, remote, and culturally diverse populations. However, evidence suggests that hospital-based strategies may not be able to deliver effective CR to these populations. Local healthcare systems may need to integrate alternative models of CR, such as brief interventions tailored to individual’s risk factor profiles, as well as community- or home-based programs, to ensure that choices are available that best fit patient’s needs, risk factor profile, and preferences.</offsets></p></sec><sec id="Sec4"><title><offsets xml_i="19273" xml_f="19328" txt_i="7628" txt_f="7683">The potential of mobile phone delivered self-management</offsets></title><p id="Par26"><offsets xml_i="19350" xml_f="19368" txt_i="7684" txt_f="7702">While telehealth [</offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="19401" xml_f="19403" txt_i="7702" txt_f="7704">24</offsets></xref><offsets xml_i="19410" xml_f="19784" txt_i="7704" txt_f="8078">] and Internet-based programs have been shown to be effective, they are limited due to predominant reliance on desktop and landline communication, whereas technology is now more mobile. Mobile phones are the most common device for communication worldwide—including developing countries—and are used to deliver behavioral-change programs and improve disease self-management [</offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="19817" xml_f="19819" txt_i="8078" txt_f="8080">25</offsets></xref><offsets xml_i="19826" xml_f="20012" txt_i="8080" txt_f="8266">]. Mobile phones have potential to influence behavior at a population level because the technology is widely available globally, inexpensive, and allows instant delivery of information [</offsets><xref ref-type="bibr" rid="CR26"><offsets xml_i="20045" xml_f="20047" txt_i="8266" txt_f="8268">26</offsets></xref><offsets xml_i="20054" xml_f="20056" txt_i="8268" txt_f="8270">].</offsets></p><p id="Par27"><offsets xml_i="20074" xml_f="20195" txt_i="8271" txt_f="8392">Text-messaging—or short message service (SMS)—is the most widely used mobile phone intervention. Two systematic reviews [</offsets><xref ref-type="bibr" rid="CR27"><offsets xml_i="20228" xml_f="20230" txt_i="8392" txt_f="8394">27</offsets></xref><offsets xml_i="20237" xml_f="20239" txt_i="8394" txt_f="8396">, </offsets><xref ref-type="bibr" rid="CR28"><offsets xml_i="20272" xml_f="20274" txt_i="8396" txt_f="8398">28</offsets></xref><offsets xml_i="20281" xml_f="20561" txt_i="8398" txt_f="8678">] support the effectiveness of SMS interventions across a range of risk behaviors (e.g., smoking) and chronic conditions (e.g., diabetes and asthma). A 24-week text-messaging intervention in the HEART trial increased walking and leisure time exercise in people who were post ACS (</offsets><italic><offsets xml_i="20569" xml_f="20570" txt_i="8678" txt_f="8679">n</offsets></italic><offsets xml_i="20579" xml_f="20636" txt_i="8679" txt_f="8736"> = 171), but did not increase maximal exercise capacity [</offsets><xref ref-type="bibr" rid="CR29"><offsets xml_i="20669" xml_f="20671" txt_i="8736" txt_f="8738">29</offsets></xref><offsets xml_i="20678" xml_f="20680" txt_i="8738" txt_f="8740">, </offsets><xref ref-type="bibr" rid="CR30"><offsets xml_i="20713" xml_f="20715" txt_i="8740" txt_f="8742">30</offsets></xref><offsets xml_i="20722" xml_f="20790" txt_i="8742" txt_f="8810">]. The TEXT ME trial—which is the largest trial in people with CVD (</offsets><italic><offsets xml_i="20798" xml_f="20799" txt_i="8810" txt_f="8811">n</offsets></italic><offsets xml_i="20808" xml_f="20817" txt_i="8811" txt_f="8820"> = 710) [</offsets><xref ref-type="bibr" rid="CR31"><offsets xml_i="20850" xml_f="20852" txt_i="8820" txt_f="8822">31</offsets></xref><offsets xml_i="20859" xml_f="21855" txt_i="8822" txt_f="9818">]—reported statistically significant positive effects on low-density lipoprotein (LDL) cholesterol, and sizeable effects on secondary outcomes such as blood pressure and physical activity. This intervention involved delivery of regular semi-personalized text messages providing advice, motivation, and information that aimed to improve diet, increase physical activity, and encourage smoking cessation. While this study represents a good initial evaluation of a text messaging intervention for enhancing CHD outcomes, future work is still required. First, it was conducted in a single center in Australia with many participants excluded due to language barriers or not owning a mobile phone, which limits its generalizability. Second, the intervention was evaluated as a stand-alone strategy, thus it was unclear whether the intervention was more or less beneficial to those in traditional programs. Third, implementation of the intervention in a real-world setting was not assessed in the study.</offsets></p><p id="Par28"><offsets xml_i="21873" xml_f="21947" txt_i="9819" txt_f="9893">We previously conducted the Text4Heart randomized controlled pilot trial (</offsets><italic><offsets xml_i="21955" xml_f="21956" txt_i="9893" txt_f="9894">n</offsets></italic><offsets xml_i="21965" xml_f="21974" txt_i="9894" txt_f="9903"> = 123) [</offsets><xref ref-type="bibr" rid="CR32"><offsets xml_i="22007" xml_f="22009" txt_i="9903" txt_f="9905">32</offsets></xref><offsets xml_i="22016" xml_f="22018" txt_i="9905" txt_f="9907">, </offsets><xref ref-type="bibr" rid="CR33"><offsets xml_i="22051" xml_f="22053" txt_i="9907" txt_f="9909">33</offsets></xref><offsets xml_i="22060" xml_f="22394" txt_i="9909" txt_f="10243">], of a 6-month theory-based program of daily text messages and a supporting website in addition to usual CR services. Using a composite measure of lifestyle change (exercise, diet, smoking, alcohol), we observed a significant treatment effect on adherence to lifestyle behaviors at 3 months (adjusted OR = 2.55, 95% CI 1.12 to 5.84; </offsets><italic><offsets xml_i="22402" xml_f="22403" txt_i="10243" txt_f="10244">p</offsets></italic><offsets xml_i="22412" xml_f="22483" txt_i="10244" txt_f="10315"> = .03), but not at 6 months (adjusted OR = 1.93, 95% CI 0.83 to 4.53; </offsets><italic><offsets xml_i="22491" xml_f="22492" txt_i="10315" txt_f="10316">p</offsets></italic><offsets xml_i="22501" xml_f="22648" txt_i="10316" txt_f="10463"> = .13). At 6 months, the intervention group had greater self-reported medication adherence (mean difference in scores: 0.58, 95% CI 0.19 to 0.97; </offsets><italic><offsets xml_i="22656" xml_f="22657" txt_i="10463" txt_f="10464">p</offsets></italic><offsets xml_i="22666" xml_f="22895" txt_i="10464" txt_f="10693"> = .004), with 51% reporting high adherence compared to 32% in the control condition. Text4Heart was also associated with lowered LDL cholesterol at 6 months compared with control (mean difference: − 0.25, 95% CI -0.49 to 0.003; </offsets><italic><offsets xml_i="22903" xml_f="22904" txt_i="10693" txt_f="10694">p</offsets></italic><offsets xml_i="22913" xml_f="23262" txt_i="10694" txt_f="11043"> = .05). Participants reported high fidelity to the text-message component of the intervention, with 85% of intervention participants reading all their messages. Text4Heart was well-received with 84% of participants reporting that the program helped them recover, and 90% of participants would have recommended it to others who had a cardiac event [</offsets><xref ref-type="bibr" rid="CR33"><offsets xml_i="23295" xml_f="23297" txt_i="11043" txt_f="11045">33</offsets></xref><offsets xml_i="23304" xml_f="23516" txt_i="11045" txt_f="11257">]. A definitive trial of Text4Heart to determine its effectiveness using an objective measure is now required to determine the sustained effect of the intervention for augmenting existing cardiovascular services.</offsets></p></sec><sec id="Sec5"><title><offsets xml_i="23548" xml_f="23552" txt_i="11259" txt_f="11263">Aims</offsets></title><p id="Par29"><offsets xml_i="23574" xml_f="23823" txt_i="11264" txt_f="11513">To determine the effectiveness and cost-effectiveness of the Text4Heart II self-management program—in addition to usual care—to improve adherence to medication and lifestyle change in people with an ACS. A second aim is to use the RE-AIM framework [</offsets><xref ref-type="bibr" rid="CR34"><offsets xml_i="23856" xml_f="23858" txt_i="11513" txt_f="11515">34</offsets></xref><offsets xml_i="23865" xml_f="24024" txt_i="11515" txt_f="11674">] to inform the potential implementation of the Text4Heart II program to augment existing CR services with two district health boards in Auckland, New Zealand.</offsets></p></sec><sec id="Sec6"><title><offsets xml_i="24056" xml_f="24066" txt_i="11676" txt_f="11686">Hypotheses</offsets></title><p id="Par30"><offsets xml_i="24088" xml_f="24089" txt_i="11687" txt_f="11688">
</offsets><list list-type="order"><list-item><p id="Par31"><offsets xml_i="24138" xml_f="24312" txt_i="11688" txt_f="11862">Text4Heart II will improve self-management of ACS, as seen by increased adherence to medication and lifestyle behaviors at 6 and 12 months compared to standard CR care alone,</offsets></p></list-item><list-item><p id="Par32"><offsets xml_i="24353" xml_f="24394" txt_i="11863" txt_f="11904">Text4Heart II will be cost-effective, and</offsets></p></list-item><list-item><p id="Par33"><offsets xml_i="24435" xml_f="24567" txt_i="11905" txt_f="12037">Text4Heart II will be imminently scalable for roll out within the existing healthcare system in New Zealand (district health boards)</offsets></p></list-item></list><offsets xml_i="24590" xml_f="24591" txt_i="12038" txt_f="12039">
</offsets></p></sec></sec><sec id="Sec7"><title><offsets xml_i="24629" xml_f="24636" txt_i="12042" txt_f="12049">Methods</offsets></title><p id="Par34"><offsets xml_i="24658" xml_f="24927" txt_i="12050" txt_f="12319">The Text4Heart II trial is a two-arm, parallel, superiority RCT conducted in two large metropolitan hospitals in Auckland, New Zealand. The study protocol is in accord with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 Statement [</offsets><xref ref-type="bibr" rid="CR35"><offsets xml_i="24960" xml_f="24962" txt_i="12319" txt_f="12321">35</offsets></xref><offsets xml_i="24969" xml_f="25219" txt_i="12321" txt_f="12571">], and was prospectively registered in the Australian New Zealand Clinical Trials Registry on 1 April 2016, (ACTRN12616000422426). The intervention is described according to the Consolidated Standards of Reporting Trials (CONSORT)-eHealth Checklist [</offsets><xref ref-type="bibr" rid="CR36"><offsets xml_i="25252" xml_f="25254" txt_i="12571" txt_f="12573">36</offsets></xref><offsets xml_i="25261" xml_f="25304" txt_i="12573" txt_f="12616">]. The trial schedule is presented in Fig. </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="25336" xml_f="25337" txt_i="12616" txt_f="12617">1</offsets></xref><offsets xml_i="25344" xml_f="25402" txt_i="12617" txt_f="12675">, and the SPIRIT Checklist is reported in Additional file </offsets><xref rid="MOESM1" ref-type="media"><offsets xml_i="25438" xml_f="25439" txt_i="12675" txt_f="12676">1</offsets></xref><offsets xml_i="25446" xml_f="25447" txt_i="12676" txt_f="12677">.</offsets><fig id="Fig1"><label><offsets xml_i="25469" xml_f="25475" txt_i="12677" txt_f="12683">Fig. 1</offsets></label><caption><p><offsets xml_i="25495" xml_f="25634" txt_i="12683" txt_f="12822">Schedule of enrollment, interventions, and assessments (Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure)</offsets></p></caption><graphic xlink:href="13063_2018_2468_Fig1_HTML" id="MO1"></graphic></fig></p><sec id="Sec8"><title><offsets xml_i="25747" xml_f="25779" txt_i="12824" txt_f="12856">Study population and recruitment</offsets></title><p id="Par35"><offsets xml_i="25801" xml_f="26429" txt_i="12857" txt_f="13485">Adults who are clinically stable, able to read English, and provide informed consent are invited to participate into the study either while inpatients, or shortly after discharge following ACS or post percutaneous coronary intervention. Exclusion criteria include untreated ventricular tachycardia, severe heart failure, life-threatening co-existing disease with life expectancy below 1 year, and significant exercise limitations other than CVD. Potential participants will be given information sheets by a researcher and informed consent will be obtained either in writing, or verbally if the participant is already discharged.</offsets></p><p id="Par36"><offsets xml_i="26447" xml_f="26609" txt_i="13486" txt_f="13648">All patients admitted with ACS or who undergo angiography are registered in the All New Zealand Acute Coronary Syndrome Quality Improvement register (ANZACS-QI) [</offsets><xref ref-type="bibr" rid="CR37"><offsets xml_i="26642" xml_f="26644" txt_i="13648" txt_f="13650">37</offsets></xref><offsets xml_i="26651" xml_f="27087" txt_i="13650" txt_f="14083">]. ANZACS-QI collects detailed information on risk factors, diagnosis, investigations, as well as management and complications during admission, and is embedded in &gt; 90% of hospitals in New Zealand. Data are able to be linked to laboratory results and dispensing from chemists. Anonymized linkage to patients’ unique National Health Index number allows data to be obtained on mortality and rehospitalization for subsequent analysis [</offsets><xref ref-type="bibr" rid="CR38"><offsets xml_i="27120" xml_f="27122" txt_i="14083" txt_f="14085">38</offsets></xref><offsets xml_i="27129" xml_f="27358" txt_i="14085" txt_f="14314">]. This study design, utilizing the strengths of the clinical registry combined with the specific clinical trial protocol, provides a unique opportunity to collect study data at low cost and with no additional participant burden.</offsets></p></sec><sec id="Sec9"><title><offsets xml_i="27390" xml_f="27401" txt_i="14316" txt_f="14327">Sample size</offsets></title><p id="Par37"><offsets xml_i="27423" xml_f="27936" txt_i="14328" txt_f="14838">A total of 330 participants (165 per group) will provide 80% power at the 5% level of significance (two-sided) to detect an absolute difference of 15% between the two groups, in the proportions of participants adherent to medication 6 months after randomization (assuming a control rate of 30%). This is a conservative control rate and is based on our self-reported Text4Heart pilot data, and New Zealand research that found only 60% of patients had a Medication Dispensing Ratio (SDR) &gt; 0.8 for statins only [</offsets><xref ref-type="bibr" rid="CR39"><offsets xml_i="27969" xml_f="27971" txt_i="14838" txt_f="14840">39</offsets></xref><offsets xml_i="27978" xml_f="28311" txt_i="14840" txt_f="15173">]. This value is likely to be lower when all classes of medication (statins, antihypertensive, and antiplatelet therapies) are considered. If the control rate was indeed 60% then a total of 304 participants would be required to detect an absolute difference of 15%; thus, we would be adequately powered with our proposed sample size.</offsets></p></sec><sec id="Sec10"><title><offsets xml_i="28344" xml_f="28395" txt_i="15175" txt_f="15226">Randomization, allocation concealment, and blinding</offsets></title><p id="Par38"><offsets xml_i="28417" xml_f="29095" txt_i="15227" txt_f="15905">Upon completion of baseline assessment a researcher will randomly allocate eligible participants at a 1:1 ratio to the intervention or control arm, using blocked (variable block sizes, 2 or 4) stratified (hospital site) randomization. The allocation sequence will be computer generated by an independent statistician not involved with trial conduct, and concealed by a centralized computer system that will reveal treatment allocation only after submission of baseline data. Study investigators (but not participants) are blinded to intervention allocation throughout the trial. The primary outcome, however, is derived from data linkage, which is blind to treatment allocation.</offsets></p></sec><sec id="Sec11"><title><offsets xml_i="29128" xml_f="29152" txt_i="15907" txt_f="15931">Intervention and control</offsets></title><p id="Par39"><offsets xml_i="29174" xml_f="29861" txt_i="15932" txt_f="16619">All participants will receive usual care, which includes CR support. In addition, those allocated to the Text4Heart II intervention arm will receive a personalized, automated program of CR delivered via text message over 24 weeks. The overall goals of the intervention are to encourage and promote adherence to medication, healthy diet, stress management, regular exercise, reduced alcohol consumption, and smoking cessation (if applicable). Participants will be able choose additional focussed intervention modules at baseline that address risk factors that they identify as most relevant to them, such as physical activity, heart healthy diet, stress management, and smoking cessation.</offsets></p><p id="Par40"><offsets xml_i="29879" xml_f="30777" txt_i="16620" txt_f="17518">Participants receive one message per day for the first 12 weeks, a technical support phone call at 12 weeks, and five messages per week for the remaining 12 weeks. Messages will be personalized (including participants’ names) and sent at times to suit participants. The intervention is predominantly unidirectional but participants will be able to reply to text messages and a researcher will answer within 24 h. All participants will be offered brief training at enrollment on how to read, delete, and save text messages. Messages are categorized into four groups (see below). Non-smokers receive one to two general heart health messages, one to two physical activity messages, and one to two dietary messages per week. Smokers receive one general heart health message, one to two physical activity messages, one to two dietary messages, and one to two smoking-cessation support messages per week.</offsets></p><p id="Par41"><offsets xml_i="30795" xml_f="31123" txt_i="17519" txt_f="17847">At registration, intervention group participants will select their preferred receipt times for educational (early morning, late morning, early afternoon, late afternoon, or evening) and medication reminder messages to ensure that the timing is appropriate for their needs. Details of the text-message content are provided below.</offsets></p></sec><sec id="Sec12"><title><offsets xml_i="31156" xml_f="31176" txt_i="17849" txt_f="17869">Intervention content</offsets></title><sec id="Sec13"><title><offsets xml_i="31207" xml_f="31252" txt_i="17870" txt_f="17915">General heart health and medication adherence</offsets></title><p id="Par42"><offsets xml_i="31274" xml_f="31956" txt_i="17916" txt_f="18598">General health information messages that include facts about risk factors and medication will be provided. Messages will include information and strategies to help participants adhere to their prescribed medication regimen—including information on the value of taking medication to reduce recurrent events and hospitalization, reminders to have a regular check-up with their physician, enhancing self-management, and addressing illness perceptions and medications beliefs. In addition, advice will be given about contacting their physician if unwell, practical tips on how to improve lifestyle though habit formation and environmental prompts, and how to enlist support from others.</offsets></p></sec><sec id="Sec14"><title><offsets xml_i="31989" xml_f="32006" txt_i="18600" txt_f="18617">Physical activity</offsets></title><p id="Par43"><offsets xml_i="32028" xml_f="32104" txt_i="18618" txt_f="18694">Participants will receive messages derived from the successful HEART trial [</offsets><xref ref-type="bibr" rid="CR29"><offsets xml_i="32137" xml_f="32139" txt_i="18694" txt_f="18696">29</offsets></xref><offsets xml_i="32146" xml_f="32148" txt_i="18696" txt_f="18698">, </offsets><xref ref-type="bibr" rid="CR30"><offsets xml_i="32181" xml_f="32183" txt_i="18698" txt_f="18700">30</offsets></xref><offsets xml_i="32190" xml_f="32516" txt_i="18700" txt_f="19026">], that address the importance of being physically active. Message content will include suggested activities, key strategies to enhance uptake and maintenance of physical activity (e.g., goal setting, self-monitoring), and a generic exercise prescription that suggests the type, frequency, duration, and intensity of exercise.</offsets></p></sec><sec id="Sec15"><title><offsets xml_i="32549" xml_f="32565" txt_i="19028" txt_f="19044">Dietary behavior</offsets></title><p id="Par44"><offsets xml_i="32587" xml_f="32792" txt_i="19045" txt_f="19250">Participants will be supported to reduce dietary saturated fat and salt intake, and to manage their weight. All content was developed, pre-tested and successfully piloted prior to the Text4Heart II trial [</offsets><xref ref-type="bibr" rid="CR40"><offsets xml_i="32825" xml_f="32827" txt_i="19250" txt_f="19252">40</offsets></xref><offsets xml_i="32834" xml_f="33029" txt_i="19252" txt_f="19447">]. Participants will receive text messages promoting healthy eating strategies, advice on choosing healthy food, and food preparation. The messages focus on supporting behavior-change strategies.</offsets></p></sec><sec id="Sec16"><title><offsets xml_i="33062" xml_f="33079" txt_i="19449" txt_f="19466">Smoking cessation</offsets></title><p id="Par45"><offsets xml_i="33101" xml_f="33227" txt_i="19467" txt_f="19593">Participants who smoke tobacco will receive components of the successful STOMP text-messaging smoking-cessation intervention [</offsets><xref ref-type="bibr" rid="CR41"><offsets xml_i="33260" xml_f="33262" txt_i="19593" txt_f="19595">41</offsets></xref><offsets xml_i="33269" xml_f="33270" txt_i="19595" txt_f="19596">–</offsets><xref ref-type="bibr" rid="CR43"><offsets xml_i="33303" xml_f="33305" txt_i="19596" txt_f="19598">43</offsets></xref><offsets xml_i="33312" xml_f="33525" txt_i="19598" txt_f="19811">]. They will be sent regular messages providing smoking-cessation advice and support (e.g., symptoms to expect on quitting, tips to avoid weight gain and to cope with craving, advice on avoiding smoking triggers).</offsets></p><p id="Par46"><offsets xml_i="33543" xml_f="33620" txt_i="19812" txt_f="19889">All messages are grounded in established psychological (Common Sense Model) [</offsets><xref ref-type="bibr" rid="CR44"><offsets xml_i="33653" xml_f="33655" txt_i="19889" txt_f="19891">44</offsets></xref><offsets xml_i="33662" xml_f="33711" txt_i="19891" txt_f="19940">] and behavior-change (Social Cognitive) theory [</offsets><xref ref-type="bibr" rid="CR45"><offsets xml_i="33744" xml_f="33746" txt_i="19940" txt_f="19942">45</offsets></xref><offsets xml_i="33753" xml_f="33927" txt_i="19942" txt_f="20116">] and will focus on modifying perceptions of the symptoms, timeline, causes, consequences, understanding of, personal control over, and ability of treatment to prevent, CVD [</offsets><xref ref-type="bibr" rid="CR46"><offsets xml_i="33960" xml_f="33962" txt_i="20116" txt_f="20118">46</offsets></xref><offsets xml_i="33969" xml_f="34085" txt_i="20118" txt_f="20234">], as well as altering the key mediators of behavior change including self-efficacy, social support, and motivation.</offsets></p></sec></sec><sec id="Sec17"><title><offsets xml_i="34124" xml_f="34132" txt_i="20237" txt_f="20245">Outcomes</offsets></title><p id="Par47"><offsets xml_i="34154" xml_f="34505" txt_i="20246" txt_f="20597">All outcomes are assessed at 6 and 12 months post randomization. The primary outcome is the proportion of participants adhering to medication at 6 months. Medication adherence is defined as SDRs of 80% for statins, antihypertensive, and antiplatelet therapy classes of medication (calculated separately)—consistent with guideline-recommended therapy [</offsets><xref ref-type="bibr" rid="CR47"><offsets xml_i="34538" xml_f="34540" txt_i="20597" txt_f="20599">47</offsets></xref><offsets xml_i="34547" xml_f="34927" txt_i="20599" txt_f="20979">]—where SDR is calculated as the number of days that the supply is obtained divided by the number of days in the observation period. Participants’ community pharmacy dispensing records will be linked using their unique National Health Index number via the National Pharmaceuticals Collection database. This approach has been used successfully in New Zealand to assess statin use [</offsets><xref ref-type="bibr" rid="CR39"><offsets xml_i="34960" xml_f="34962" txt_i="20979" txt_f="20981">39</offsets></xref><offsets xml_i="34969" xml_f="35529" txt_i="20981" txt_f="21541">]. To adjust for days not covered due to death or days spent in hospital these periods are subtracted from the 6-month coverage time. The number of days supplied will be estimated from strength per unit and daily dose variables summed from pharmacy claims during the observation period. To account for any previous supply of the medication (before discharge), medication claims in the 3 months prior to admission are collected. The SDR for each class of medication (statins, antihypertensive, and antiplatelet therapies) will be recorded as secondary outcomes.</offsets></p></sec><sec id="Sec18"><title><offsets xml_i="35562" xml_f="35580" txt_i="21543" txt_f="21561">Secondary outcomes</offsets></title><p id="Par48"><offsets xml_i="35602" xml_f="35952" txt_i="21562" txt_f="21912">In a similar manner to the primary outcome, the proportion of participants adhering to medication will be assessed at 12 months. Self-reported outcomes will be measured by a trained research assistant during a telephone call at 6 and 12 months. Self-reported medication adherence will be assessed using the Morisky 8-item Medication Adherence Scale [</offsets><xref ref-type="bibr" rid="CR48"><offsets xml_i="35985" xml_f="35987" txt_i="21912" txt_f="21914">48</offsets></xref><offsets xml_i="35994" xml_f="36032" txt_i="21914" txt_f="21952">]. As per the Text4Heart pilot trial [</offsets><xref ref-type="bibr" rid="CR32"><offsets xml_i="36065" xml_f="36067" txt_i="21952" txt_f="21954">32</offsets></xref><offsets xml_i="36074" xml_f="36076" txt_i="21954" txt_f="21956">, </offsets><xref ref-type="bibr" rid="CR33"><offsets xml_i="36109" xml_f="36111" txt_i="21956" txt_f="21958">33</offsets></xref><offsets xml_i="36118" xml_f="36283" txt_i="21958" txt_f="22123">], adherence to recommended lifestyle behaviors will be measured using a composite health behavior score adapted from the EPIC-Norfolk Prospective Population Study [</offsets><xref ref-type="bibr" rid="CR49"><offsets xml_i="36316" xml_f="36318" txt_i="22123" txt_f="22125">49</offsets></xref><offsets xml_i="36325" xml_f="36414" txt_i="22125" txt_f="22214">]. The following measures will be used to determine participants’ health behavior scores:</offsets><list list-type="order"><list-item><p id="Par49"><offsets xml_i="36463" xml_f="36561" txt_i="22214" txt_f="22312">Smoking status will be measured using three items from a validated smoking history questionnaire [</offsets><xref ref-type="bibr" rid="CR50"><offsets xml_i="36594" xml_f="36596" txt_i="22312" txt_f="22314">50</offsets></xref><offsets xml_i="36603" xml_f="36741" txt_i="22314" txt_f="22452">] including whether participants have ever smoked, have had a puff of tobacco in the last week and when they quit smoking (if appropriate)</offsets></p></list-item><list-item><p id="Par50"><offsets xml_i="36782" xml_f="36894" txt_i="22453" txt_f="22565">Physical activity level will be assessed using the Godin Leisure Time Physical Activity Questionnaire (GLTPAQ) [</offsets><xref ref-type="bibr" rid="CR51"><offsets xml_i="36927" xml_f="36929" txt_i="22565" txt_f="22567">51</offsets></xref><offsets xml_i="36936" xml_f="37066" txt_i="22567" txt_f="22697">]. This simple, three-item questionnaire has well-established reliability and validity and has been used in patients undergoing CR</offsets></p></list-item><list-item><p id="Par51"><offsets xml_i="37107" xml_f="37237" txt_i="22698" txt_f="22828">Alcohol consumption will be measured using the Alcohol Use Disorders Identification Test alcohol consumption questions (AUDIT-C) [</offsets><xref ref-type="bibr" rid="CR52"><offsets xml_i="37270" xml_f="37272" txt_i="22828" txt_f="22830">52</offsets></xref><offsets xml_i="37279" xml_f="37489" txt_i="22830" txt_f="23040">]—a screening tool designed to assess units of alcohol consumed per week, and identify people who are hazardous drinkers. Index cards referencing standard drink sizes will be used to reduce comprehension errors</offsets></p></list-item><list-item><p id="Par52"><offsets xml_i="37530" xml_f="37657" txt_i="23041" txt_f="23168">Fruit and vegetable intake are assessed by two New Zealand-specific questions used in the 2006/2007 New Zealand Health Survey (</offsets><italic><offsets xml_i="37665" xml_f="37666" txt_i="23168" txt_f="23169">n</offsets></italic><offsets xml_i="37675" xml_f="37714" txt_i="23169" txt_f="23208"> = 12,488, including adults with CHD) [</offsets><xref ref-type="bibr" rid="CR53"><offsets xml_i="37747" xml_f="37749" txt_i="23208" txt_f="23210">53</offsets></xref><offsets xml_i="37756" xml_f="37757" txt_i="23210" txt_f="23211">]</offsets></p></list-item></list></p><p id="Par53"><offsets xml_i="37798" xml_f="38180" txt_i="23213" txt_f="23595">Participants receive a score on a 4-point scale for each of the four key risk factors, with 1 point each assigned for being a current non-smoker, meeting physical activity guidelines to achieve some health benefits (defined as ≥ 14 units on the GLTPAQ), consuming ≤ 14 standard units of alcohol per week, and consuming at least five servings of fruit and vegetables per typical day.</offsets></p><p id="Par54"><offsets xml_i="38198" xml_f="38803" txt_i="23596" txt_f="24201">Using participants’ encrypted National Health Index identification numbers we will be able to obtain clinical data (lipid profiles and blood pressure) from the ANZACS-QI database to maximize collection of these outcomes. Data describing hospital events, clinical information, as well as medication prescribing and dispensing will also be captured. For the purpose of this trial we will access data on lipid profile (total/LDL/HDL cholesterol) and blood pressure, from admission and routine follow-ups. Using ANZACS-QI we will also be able to access information on readmissions and related hospital events.</offsets></p><p id="Par55"><offsets xml_i="38821" xml_f="39221" txt_i="24202" txt_f="24602">Intervention delivery costs—including text-message service and per message costs as well as health service staff time for recruitment and program facilitation—will be collected. Any changes in health service utilization observed between intervention and control groups will lead to an estimation of the costs of those changes with the assistance of District Health Board funding information analysts.</offsets></p></sec><sec id="Sec19"><title><offsets xml_i="39254" xml_f="39268" txt_i="24604" txt_f="24618">Adverse events</offsets></title><p id="Par56"><offsets xml_i="39290" xml_f="39542" txt_i="24619" txt_f="24871">All participants will continue with their usual care for ACS. No individual clinical advice is given through the pre-programmed text messages. We will be evaluating hospitalizations or health service utilization as part of the outcomes specified above.</offsets></p></sec><sec id="Sec20"><title><offsets xml_i="39575" xml_f="39595" txt_i="24873" txt_f="24893">Statistical analysis</offsets></title><p id="Par57"><offsets xml_i="39617" xml_f="41133" txt_i="24894" txt_f="26410">Trial data collected from all eligible participants will be linked with the national ANZACS-QI database using participants’ encrypted National Health Index number for the purpose of analysis. Treatment evaluations will be performed on the principle of intention-to-treat (ITT). Missing data on the primary outcome will be considered as non-adherence in the ITT approach. Sensitivity analyses will be conducted to test the robustness of main findings using different assumptions on the missing data if the proportion of missing exceeds 10%. The proportion of participants adhering to medication at 6 months, with or without intervention, will first be summarized as frequency and percentage. Logistic regression will be conducted to evaluate the main treatment effect (OR and 95% CI), adjusting for pre-defined baseline prognostic factors. For all secondary outcomes collected at 6 and 12 months post randomization, generalized linear regression models will be used to test the effect of intervention between two groups, using a link function appropriate to the distribution of outcomes. More specifically, an identity link will be used for continuous outcomes under normal distribution and a logit link for binary outcomes under binomial distribution. Regression models will adjust for baseline outcome value (where collected) and stratification factor. Model-adjusted estimate (mean difference for continuous outcomes and OR for binary outcomes) will be reported at each scheduled visit, with 95% CI and associated </offsets><italic><offsets xml_i="41141" xml_f="41142" txt_i="26410" txt_f="26411">p</offsets></italic><offsets xml_i="41151" xml_f="41422" txt_i="26411" txt_f="26682"> value. Missing data will not be imputed on secondary outcomes without adjustment for multiple testing. Statistical analysis will be performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). All statistical tests will be two-sided at the 5% significance level.</offsets></p><sec id="Sec21"><title><offsets xml_i="41449" xml_f="41476" txt_i="26683" txt_f="26710">Cost-effectiveness analysis</offsets></title><p id="Par58"><offsets xml_i="41498" xml_f="42435" txt_i="26711" txt_f="27648">This analysis will adopt a health system perspective. We will use the EQ-5D—a generic and validated measure of quality of life for which reliable New Zealand population preference values are available—to obtain a single preference index for calculation of Quality-adjusted life-years (QALYs) to assess cost per QALY, for comparison with other programs. The incremental cost of making one extra participant adherent to CR using the intervention compared to usual care will be calculated. Ninety-five percent confidence intervals for incremental cost-effectiveness ratios, 95% confidence ellipses on the incremental cost-effectiveness plane, and cost-effectiveness acceptability curves will be calculated to compare the intervention with usual care. Markov modeling will combine these data with other information from a systematic review of cost-effectiveness studies of CR to identify the long-term cost-effectiveness of the intervention.</offsets></p></sec></sec><sec id="Sec22"><title><offsets xml_i="42474" xml_f="42489" txt_i="27651" txt_f="27666">Data management</offsets></title><p id="Par59"><offsets xml_i="42511" xml_f="42747" txt_i="27667" txt_f="27903">Data will be entered into an electronic collection system provided by Enigma Solutions which will be linked to the ANZACS-QI register. Range checks will be implemented and 10% of data will be checked for consistency against source data.</offsets></p></sec><sec id="Sec23"><title><offsets xml_i="42780" xml_f="42805" txt_i="27905" txt_f="27930">Evaluating implementation</offsets></title><p id="Par60"><offsets xml_i="42827" xml_f="42897" txt_i="27931" txt_f="28001">We propose using the RE-AIM model proposed by Glasgow and colleagues [</offsets><xref ref-type="bibr" rid="CR34"><offsets xml_i="42930" xml_f="42932" txt_i="28001" txt_f="28003">34</offsets></xref><offsets xml_i="42939" xml_f="42941" txt_i="28003" txt_f="28005">, </offsets><xref ref-type="bibr" rid="CR54"><offsets xml_i="42974" xml_f="42976" txt_i="28005" txt_f="28007">54</offsets></xref><offsets xml_i="42983" xml_f="43305" txt_i="28007" txt_f="28329">] to determine uptake and sustainability of the intervention. The RE-AIM framework—which emphasizes collecting information about the Reach, Effectiveness, Adoption, Implementation, and Maintenance of an intervention—is an evaluative framework for guiding the evaluation and reporting of health intervention effectiveness [</offsets><xref ref-type="bibr" rid="CR55"><offsets xml_i="43338" xml_f="43340" txt_i="28329" txt_f="28331">55</offsets></xref><offsets xml_i="43347" xml_f="43636" txt_i="28331" txt_f="28620">]. Further, RE-AIM provides a framework for determining which programs work under real-world conditions and which programs should be sustained. The RE-AIM framework is an ideal tool to use as the basis for planning and evaluating the success of mobile phone self-management interventions [</offsets><xref ref-type="bibr" rid="CR56"><offsets xml_i="43669" xml_f="43671" txt_i="28620" txt_f="28622">56</offsets></xref><offsets xml_i="43678" xml_f="43680" txt_i="28622" txt_f="28624">, </offsets><xref ref-type="bibr" rid="CR57"><offsets xml_i="43713" xml_f="43715" txt_i="28624" txt_f="28626">57</offsets></xref><offsets xml_i="43722" xml_f="43932" txt_i="28626" txt_f="28836">]. It also aligns with systems-based approaches and allows for assessment of vertical (e.g., adoption decisions within a given organization) and horizontal (e.g., adoption across different sectors) components [</offsets><xref ref-type="bibr" rid="CR58"><offsets xml_i="43965" xml_f="43967" txt_i="28836" txt_f="28838">58</offsets></xref><offsets xml_i="43974" xml_f="44132" txt_i="28838" txt_f="28996">]. The RE-AIM framework includes both individual- and setting/staff-level variables. Two dimensions operate at the individual level (reach and effectiveness).</offsets></p><p id="Par61"><offsets xml_i="44150" xml_f="44176" txt_i="28997" txt_f="29023">A mixed-methods approach [</offsets><xref ref-type="bibr" rid="CR59"><offsets xml_i="44209" xml_f="44211" txt_i="29023" txt_f="29025">59</offsets></xref><offsets xml_i="44218" xml_f="44475" txt_i="29025" txt_f="29282">] will be used to assess the key components of RE-AIM. Qualitative and quantitative data will be combined to thoroughly understand the extent to which the self-management intervention could be successfully implemented within the New Zealand health context [</offsets><xref ref-type="bibr" rid="CR60"><offsets xml_i="44508" xml_f="44510" txt_i="29282" txt_f="29284">60</offsets></xref><offsets xml_i="44517" xml_f="44616" txt_i="29284" txt_f="29383">]. To achieve this, data will be collected on each RE-AIM dimension as proposed by Kessler et al. [</offsets><xref ref-type="bibr" rid="CR61"><offsets xml_i="44649" xml_f="44651" txt_i="29383" txt_f="29385">61</offsets></xref><offsets xml_i="44658" xml_f="44673" txt_i="29385" txt_f="29400">] and Glasgow [</offsets><xref ref-type="bibr" rid="CR60"><offsets xml_i="44706" xml_f="44708" txt_i="29400" txt_f="29402">60</offsets></xref><offsets xml_i="44715" xml_f="44929" txt_i="29402" txt_f="29616">]. Some of these data will be collected as part of the trial (e.g., data to inform reach, effectiveness and costs/resources). Additional data will be collected specifically for the RE-AIM analysis (detailed below).</offsets></p><p id="Par62"><offsets xml_i="44947" xml_f="45209" txt_i="29617" txt_f="29879">To determine intervention reach, we will assess the number of people who participate as a proportion of those who are eligible, compare the characteristics of those who do and do not participate, and provide detailed information of reach and recruitment issues [</offsets><xref ref-type="bibr" rid="CR62"><offsets xml_i="45242" xml_f="45244" txt_i="29879" txt_f="29881">62</offsets></xref><offsets xml_i="45251" xml_f="45253" txt_i="29881" txt_f="29883">, </offsets><xref ref-type="bibr" rid="CR63"><offsets xml_i="45286" xml_f="45288" txt_i="29883" txt_f="29885">63</offsets></xref><offsets xml_i="45295" xml_f="46019" txt_i="29885" txt_f="30609">]. To achieve this, all potential participants approached about the study will be screened and basic information collected. Those who decline participation will have their information permanently de-identified. Screening information will be used to determine the representativeness of those who agree to participate compared to those who decline. Qualitative data will be gathered from those who decline about their reasons for choosing to not participate. For those who agree, a brief semi-structured interview will be conducted to determine their perspectives of the proposed intervention, their current self-management behaviors, and any concerns they might have that would have impacted on their involvement or adoption.</offsets></p><p id="Par63"><offsets xml_i="46037" xml_f="46218" txt_i="30610" txt_f="30791">In addition to the primary outcome, biological-, psychosocial-, demographic-, and program-specific parameters will be assessed as potential moderators of intervention effectiveness.</offsets></p><p id="Par64"><offsets xml_i="46236" xml_f="46365" txt_i="30792" txt_f="30921">RE-AIM dimensions Adoption, Implementation, and Maintenance will be assessed from both provider and organizational perspectives [</offsets><xref ref-type="bibr" rid="CR54"><offsets xml_i="46398" xml_f="46400" txt_i="30921" txt_f="30923">54</offsets></xref><offsets xml_i="46407" xml_f="47206" txt_i="30923" txt_f="31722">]. Key informant interviews will be conducted with stakeholders (medical practitioners and allied health staff) to obtain qualitative data from providers across these three RE-AIM dimensions, to determine factors that may enhance organizational adoption and maintenance, and potential adaptations to heighten the likelihood of consistent delivery across providers and locations. Quantitative assessment of implementation will be determined by measuring text-message responses where appropriate. Maintenance at the organizational level will be determined by conducting key informant interviews with stakeholders (e.g., chief executive officers) as well as government and non-government agencies (Ministry of Health, Heart Foundation) examining potential sustainability options for each organization [</offsets><xref ref-type="bibr" rid="CR64"><offsets xml_i="47239" xml_f="47241" txt_i="31722" txt_f="31724">64</offsets></xref><offsets xml_i="47248" xml_f="47671" txt_i="31724" txt_f="32147">]. To evaluate Maintenance at the patient level, patient outcomes will be measured at 12 months via ANZACS-QI. Long-term attrition (%) and differential rates by patient characteristics or treatment condition will be examined. At the organizational level, we will collect data on whether the interventions were sustained at more than 6 months post study funding, or which elements were retained after the program was funded.</offsets></p><p id="Par65"><offsets xml_i="47689" xml_f="48508" txt_i="32148" txt_f="32967">Qualitative data collection and analysis will be conducted by a trained and experienced researcher. Interviews will be digitally recorded and transcribed. Data will be entered using NVivo software to enable qualitative analysis. An inductive analysis approach will be used to identify the key themes to emerge from the data. These data will be collated according to each domain of the RE-AIM framework. These data sources will be combined and—together with the advisory group—investigators will make recommendations to determine the extent to which the self-management intervention achieved the desired RE-AIM outcomes. This approach has been successfully used with other behavior-change interventions and will also be valuable for informing optimal scenarios for funding and implementing this self-management program [</offsets><xref ref-type="bibr" rid="CR54"><offsets xml_i="48541" xml_f="48543" txt_i="32967" txt_f="32969">54</offsets></xref><offsets xml_i="48550" xml_f="48552" txt_i="32969" txt_f="32971">, </offsets><xref ref-type="bibr" rid="CR65"><offsets xml_i="48585" xml_f="48587" txt_i="32971" txt_f="32973">65</offsets></xref><offsets xml_i="48594" xml_f="48596" txt_i="32973" txt_f="32975">, </offsets><xref ref-type="bibr" rid="CR66"><offsets xml_i="48629" xml_f="48631" txt_i="32975" txt_f="32977">66</offsets></xref><offsets xml_i="48638" xml_f="48640" txt_i="32977" txt_f="32979">].</offsets></p></sec></sec><sec id="Sec24"><title><offsets xml_i="48679" xml_f="48689" txt_i="32982" txt_f="32992">Discussion</offsets></title><p id="Par66"><offsets xml_i="48711" xml_f="49323" txt_i="32993" txt_f="33605">The Text4Heart II trial will determine the effectiveness of a text-message-based intervention in addition to usual care for improving adherence to medication and lifestyle behaviors at both 6 and 12 months. Using the RE-AIM framework this trial will provide much needed data and insight into the potential implementation of Text4Heart II to augment existing cardiac services within two major metropolitan hospitals. The protocol, in accordance with the SPIRIT Statement, includes outcomes from recent systematic reviews of mobile health with the aim of adding quality evidence to the body of academic literature.</offsets></p><p id="Par67"><offsets xml_i="49341" xml_f="49418" txt_i="33606" txt_f="33683">This trial addresses many limitations/criticisms of previous mHealth trials [</offsets><xref ref-type="bibr" rid="CR43"><offsets xml_i="49451" xml_f="49453" txt_i="33683" txt_f="33685">43</offsets></xref><offsets xml_i="49460" xml_f="49462" txt_i="33685" txt_f="33687">, </offsets><xref ref-type="bibr" rid="CR67"><offsets xml_i="49495" xml_f="49497" txt_i="33687" txt_f="33689">67</offsets></xref><offsets xml_i="49504" xml_f="50485" txt_i="33689" txt_f="34670">]; it builds on the Text4Heart pilot trial, is adequately powered, has sufficient duration to elicit behavior change, and the follow-up assessments (6 and 12 months) are long enough to determine the sustained effect of the intervention. We also outline the behavior-change theory used, and intervention content, which will enhance its replicability. Using data linkage (National Pharmaceuticals Collection and ANZACS-QI registries) our Text4Heart II trial will not only provide an objective measurement of medication adherence, but will be one of the first of its kind to provide much needed data on sustained effects on clinical outcomes including hospitalization and mortality. While mHealth is often touted as a low-cost intervention that can be delivered at scale, few studies provide evidence of this. The Text4Heart II trial will also provide much needed data on the cost-effectiveness of this approach, and its potential implementation and scalability as a national service.</offsets></p><p id="Par68"><offsets xml_i="50503" xml_f="51171" txt_i="34671" txt_f="35339">In summary, Text4Heart II should produce new knowledge on the effectiveness and cost-effectiveness of an innovative and promising mHealth program to improve self-management of heart disease. It extends previous research by investigating the sustained effects of a text-message intervention, and will offer unique insights into clinical effects. If effective, this approach could substantially reduce deaths and hospital admissions in a group of patients who account for up to one third of all hospital admissions. We will provide much needed insight into the potential of implementing this program at a national level, thereby augmenting existing CVD service delivery.</offsets></p><sec id="Sec25"><title><offsets xml_i="51198" xml_f="51210" txt_i="35340" txt_f="35352">Trial status</offsets></title><p id="Par69"><offsets xml_i="51232" xml_f="51866" txt_i="35353" txt_f="35987">Recruitment for the Text4Heart II trial opened in July 2016 at Auckland City and North Shore Hospitals (Auckland, New Zealand). Recruitment is currently open, and expected to be completed in October 2017. The original study protocol was finalized on 18 March 2016; this manuscript reports version 5, amended on 13 December 2016. The primary amendment extended follow-up to 12 months, facilitated by an award from National Heart Foundation of New Zealand. Version control has been implemented to document all amendments to the study protocol, and these will be communicated to the Ethics Committees and trial investigators as required.</offsets></p></sec></sec></body><back><app-group><app id="App1"><sec id="Sec26"><title>Additional file</title><p id="Par77">
<media position="anchor" xlink:href="13063_2018_2468_MOESM1_ESM.doc" id="MOESM1"><label>Additional file 1:</label><caption><p>SPIRIT Checklist. (DOC 120 kb)</p></caption></media>
</p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>ACS</term><def><p id="Par6">Acute coronary syndrome</p></def></def-item><def-item><term>ANZACS-QI</term><def><p id="Par7">All New Zealand Acute Coronary Syndrome Quality Improvement register</p></def></def-item><def-item><term>AUDIT-C</term><def><p id="Par8">Alcohol Use Disorders Identification Test</p></def></def-item><def-item><term>CHD</term><def><p id="Par9">Coronary heart disease</p></def></def-item><def-item><term>CR</term><def><p id="Par10">Cardiac rehabilitation</p></def></def-item><def-item><term>CVD</term><def><p id="Par11">Cardiovascular disease</p></def></def-item><def-item><term>GLTPAQ</term><def><p id="Par12">Godin Leisure Time Physical Activity Questionnaire</p></def></def-item><def-item><term>ITT</term><def><p id="Par13">Intention-to-treat</p></def></def-item><def-item><term>LDL</term><def><p id="Par14">Low-density lipoprotein</p></def></def-item><def-item><term>MI</term><def><p id="Par15">Myocardial infarction</p></def></def-item><def-item><term>OR</term><def><p id="Par16">Odds ratio</p></def></def-item><def-item><term>QALY</term><def><p id="Par17">Quality-adjusted life-year</p></def></def-item><def-item><term>SDR</term><def><p id="Par18">Medication Dispensing Ratio</p></def></def-item><def-item><term>SMS</term><def><p id="Par19">Short message service</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (10.1186/s13063-018-2468-z) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable</p><sec id="FPar1"><title>Funding</title><p id="Par70">Financial support for this trial is being provided by the Health Research Council of New Zealand (15/667) and National Heart Foundation of New Zealand (1684). In-kind support is being provided by the Auckland and Waitemata District Health Boards. Funders will have no involvement in the study design; data collection, management, analysis, and interpretation; report writing; or decision to submit the reports for publication.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par71">Not applicable</p></sec><sec id="FPar3"><title>Dissemination policy</title><p id="Par72">A dissemination policy has yet to be finalized and signed by all investigators, but will include peer reviewed publications, conference presentations, and a media release.</p></sec></ack><notes notes-type="author-contribution"><title>Authors’ contributions </title><p>RM conceived of the study, its design, and led drafting of the manuscript. RS contributed clinical expertise for the trial design and refined the study protocol. RD contributed clinical expertise for the trial design and refined the study protocol. TS contributed clinical expertise for the trial design and refined the study protocol. AK contributed clinical expertise for the trial design and refined the study protocol. JB contributed clinical expertise for the trial design and refined the study protocol. RW contributed to the trial design and refinement of the study protocol. JR contributed to the trial design and refinement of the study protocol. AR contributed to the trial design and refinement of the study protocol. YJ contributed statistical expertise and will conduct the primary analyses. PE contributed to the trial design and refinement of the study protocol. RKS contributed to the trial design and refinement of the study protocol. HB contributed to the trial design and refinement of the study protocol. LPD contributed to the trial design and refinement of the study protocol. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar4"><title>Ethics approval and consent to participate</title><p id="Par73">Text4Heart II received ethical approval from the New Zealand Health and Disability Ethics Committee, Northern A (15/NTA/205); internal approval was also granted by the Auckland and Waitemata District Health Board Research Review Committees. All participants will provide written or verbal consent as described above.</p></sec><sec id="FPar5"><title>Consent for publication</title><p id="Par74">Not applicable</p></sec><sec id="FPar6"><title>Competing interests</title><p id="Par75">The authors declare that they have no competing interests.</p></sec><sec id="FPar7"><title>Publisher’s Note</title><p id="Par76">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">World Health Organisation: Cardiovascular diseases (CVDs): Fact sheet [<ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs317/en/index.html">http://www.who.int/mediacentre/factsheets/fs317/en/index.html</ext-link> and archived at <ext-link ext-link-type="uri" xlink:href="http://www.webcitation.org/6whJmvZ1h">http://www.webcitation.org/6whJmvZ1h</ext-link>.</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>WC</given-names></name><name><surname>Wright</surname><given-names>C</given-names></name><name><surname>Riddell</surname><given-names>T</given-names></name><name><surname>Wells</surname><given-names>S</given-names></name><name><surname>Kerr</surname><given-names>AJ</given-names></name><name><surname>Gala</surname><given-names>G</given-names></name><name><surname>Jackson</surname><given-names>R</given-names></name></person-group><article-title>Ethnic and socioeconomic disparities in the prevalence of cardiovascular disease in New Zealand</article-title><source>N Z Med J</source><year>2008</year><volume>121</volume><issue>1285</issue><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">19079433</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">National Center for Chronic Disease Prevention and Health. Heart Disease and Stroke Prevention: Addressing the Nation's Leading Killers: At A Glance 2011. In. Georgia, USA: Centers for Disease Control and Prevention; 2011.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Australian Institute of Health and Welfare</collab></person-group><source>Cardiovascular, diabetes and chronic kidney disease series</source><year>2014</year><publisher-loc>Canberra, Australia</publisher-loc><publisher-name>AIHW</publisher-name></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mozaffarian</surname><given-names>D</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Arnett</surname><given-names>DK</given-names></name><name><surname>Blaha</surname><given-names>MJ</given-names></name><name><surname>Cushman</surname><given-names>M</given-names></name><name><surname>de Ferranti</surname><given-names>S</given-names></name><name><surname>Despres</surname><given-names>JP</given-names></name><name><surname>Fullerton</surname><given-names>HJ</given-names></name><name><surname>Howard</surname><given-names>VJ</given-names></name><etal></etal></person-group><article-title>Heart disease and stroke statistics—2015 update: a report from the American Heart Association</article-title><source>Circulation</source><year>2015</year><volume>131</volume><issue>4</issue><fpage>e29</fpage><lpage>e322</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000000152</pub-id><pub-id pub-id-type="pmid">25520374</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">World Health Organisation: Non-communicable diseases: Factsheet. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs355/en/">http://www.who.int/mediacentre/factsheets/fs355/en/</ext-link> and archived at <ext-link ext-link-type="uri" xlink:href="http://www.webcitation.org/6whLfLksM">http://www.webcitation.org/6whLfLksM</ext-link>.</mixed-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>R</given-names></name><name><surname>Kirby</surname><given-names>B</given-names></name></person-group><article-title>The evidence base for the cost-effectiveness of cardiac rehabilitation</article-title><source>Heart</source><year>1997</year><volume>78</volume><issue>1</issue><fpage>5</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1136/hrt.78.1.5</pub-id><pub-id pub-id-type="pmid">9290390</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardetto</surname><given-names>N</given-names></name></person-group><article-title>Self-management in heart failure: where have we been and where should we go?</article-title><source>J Multidiscip Healthc</source><year>2011</year><volume>4</volume><fpage>39</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.2147/JMDH.S8174</pub-id><pub-id pub-id-type="pmid">21544247</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>WP</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Pwee</surname><given-names>KH</given-names></name><name><surname>Lim</surname><given-names>J</given-names></name></person-group><article-title>A systematic review of economic evaluations of cardiac rehabilitation</article-title><source>BMC Health Serv Res</source><year>2012</year><volume>12</volume><fpage>243</fpage><pub-id pub-id-type="doi">10.1186/1472-6963-12-243</pub-id><pub-id pub-id-type="pmid">22873828</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Jolliffe J, Rees K, Taylor RRS, Thompson DR, Oldridge N, Ebrahim S: Exercise-based rehabilitation for coronary heart disease. Cochrane Database Sys Rev. 2009(1). 10.1002/14651858.CD14001800.</mixed-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iestra</surname><given-names>JA</given-names></name><name><surname>Kromhout</surname><given-names>YT</given-names></name><name><surname>Schouw</surname><given-names>VD</given-names></name><name><surname>Grobbee</surname><given-names>DE</given-names></name><name><surname>Boshuizen</surname><given-names>HC</given-names></name><name><surname>van Staveren</surname><given-names>WA</given-names></name></person-group><article-title>Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review</article-title><source>Circulation</source><year>2005</year><volume>112</volume><fpage>924</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.104.503995</pub-id><pub-id pub-id-type="pmid">16087812</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bethell</surname><given-names>HJN</given-names></name><name><surname>Evans</surname><given-names>JA</given-names></name><name><surname>Turner</surname><given-names>SC</given-names></name><name><surname>Lewin</surname><given-names>RJ</given-names></name></person-group><article-title>The rise and fall of cardiac rehabilitation in the United Kingdom since 1998</article-title><source>J Public Health</source><year>2006</year><volume>29</volume><issue>1</issue><fpage>57</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1093/pubmed/fdl091</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bethell</surname><given-names>HJN</given-names></name><name><surname>Lewin</surname><given-names>RJ</given-names></name><name><surname>Dalal</surname><given-names>HM</given-names></name></person-group><article-title>Cardiac rehabilitation in the United Kingdom</article-title><source>Heart</source><year>2009</year><volume>95</volume><fpage>271</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1136/hrt.2007.134338</pub-id><pub-id pub-id-type="pmid">18208830</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Suaya JA, Shepard DS, Normand S-LT, Ades PA, Prottas J, Stason WB. Use of cardiac rehabilitation by Medicare beneficiaries after myocardial infarction or coronary bypass surgery. Circulation. 2007;116(15):1653–62. 10.1161/circulationaha.107.701466.</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>AT</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name></person-group><article-title>Patient characteristics, compliance, and exercise outcomes of South Asians enrolled in cardiac rehabilitation</article-title><source>J Cardiopulm Rehabil Prev</source><year>2007</year><volume>27</volume><issue>4</issue><fpage>212</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1097/01.HCR.0000281765.52158.be</pub-id><pub-id pub-id-type="pmid">17667016</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walters</surname><given-names>DL</given-names></name><name><surname>Aroney</surname><given-names>CN</given-names></name><name><surname>Chew</surname><given-names>DP</given-names></name><name><surname>Bungey</surname><given-names>L</given-names></name><name><surname>Coverdale</surname><given-names>SG</given-names></name><name><surname>Allan</surname><given-names>R</given-names></name><name><surname>Brieger</surname><given-names>D</given-names></name></person-group><article-title>Variations in the application of cardiac care in Australia</article-title><source>Med J Aust</source><year>2008</year><volume>188</volume><issue>4</issue><fpage>218</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">18279128</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doolan-Noble</surname><given-names>F</given-names></name><name><surname>Broad</surname><given-names>J</given-names></name><name><surname>Riddell</surname><given-names>T</given-names></name><name><surname>North</surname><given-names>D</given-names></name></person-group><article-title>Cardiac rehabilitation services in New Zealand: access and utilisation</article-title><source>N Z Med J</source><year>2004</year><volume>117</volume><issue>1197</issue><fpage>1</fpage><lpage>12</lpage></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bethell</surname><given-names>HJN</given-names></name></person-group><article-title>Exercise in cardiac rehabilitation</article-title><source>Br J Sports Med</source><year>1999</year><volume>33</volume><fpage>79</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1136/bjsm.33.2.79</pub-id><pub-id pub-id-type="pmid">10205687</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Daly J, Sindone AP, Thompson DR, Hancock K, Chang E, Davidson P. Barriers to participation in and adherence to cardiac rehabilitation programs: a critical literature review. Prog Cardiovasc Nurs. 2002;17(1):8–17. 10.1111/j.0889-7204.2002.00614.x.</mixed-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunlay</surname><given-names>S</given-names></name><name><surname>Witt</surname><given-names>B</given-names></name><name><surname>Allison</surname><given-names>T</given-names></name><name><surname>Hayes</surname><given-names>S</given-names></name><name><surname>Weston</surname><given-names>S</given-names></name><name><surname>Koepsell</surname><given-names>E</given-names></name><name><surname>Roger</surname><given-names>V</given-names></name></person-group><article-title>Barriers to participation in cardiac rehabilitation</article-title><source>Am Heart J</source><year>2009</year><volume>158</volume><issue>5</issue><fpage>852</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2009.08.010</pub-id><pub-id pub-id-type="pmid">19853708</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Beswick AD, Rees K, West RR, Taylor FC, Burke M, Griebsch I, Taylor RS, Victory J, Brown J, Ebrahim S. Improving uptake and adherence in cardiac rehabilitation: literature review. J Adv Nurs. 2005;49(5):538–55. 10.1111/j.1365-2648.2004.03327.x.</mixed-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>R</given-names></name><name><surname>Conway</surname><given-names>A</given-names></name><name><surname>Poulsen</surname><given-names>V</given-names></name><name><surname>Keech</surname><given-names>W</given-names></name><name><surname>Tirimacco</surname><given-names>R</given-names></name><name><surname>Tideman</surname><given-names>P</given-names></name></person-group><article-title>Alternative models of cardiac rehabilitation: a systematic review</article-title><source>Eur J Prev Cardiol</source><year>2015</year><volume>22</volume><issue>1</issue><fpage>35</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1177/2047487313501093</pub-id><pub-id pub-id-type="pmid">23943649</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalal</surname><given-names>HM</given-names></name><name><surname>Evans</surname><given-names>P</given-names></name></person-group><article-title>Achieving national service framework standards for cardiac rehabilitation and secondary prevention</article-title><source>Br Med J</source><year>2003</year><volume>326</volume><fpage>481</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1136/bmj.326.7387.481</pub-id><pub-id pub-id-type="pmid">12609946</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Neubeck L, Redfern J, Fernandez R, Briffa T, Bauman A, Freedman SB. Telehealth interventions for the secondary prevention of coronary heart disease: a systematic review. Eur J Cardiovasc Prev Rehabil. 2009;16:281–9. 10.1097/HJR.0b013e32832a4e7a.</mixed-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfaeffli Dale</surname><given-names>L</given-names></name><name><surname>Dobson</surname><given-names>R</given-names></name><name><surname>Whittaker</surname><given-names>R</given-names></name><name><surname>Maddison</surname><given-names>R</given-names></name></person-group><article-title>The effectiveness of mobile-health behaviour change interventions for cardiovascular disease self-management: a systematic review</article-title><source>Eur J Prev Cardiol</source><year>2016</year><volume>23</volume><issue>8</issue><fpage>801</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1177/2047487315613462</pub-id><pub-id pub-id-type="pmid">26490093</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Cole-Lewis H, Kershaw T. Text messaging as a tool for behavior change in disease prevention and management. Epidemiol Rev. 2010;32(1):56–69. 10.1093/epirev/mxq004.</mixed-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishna</surname><given-names>S</given-names></name><name><surname>Boren</surname><given-names>S</given-names></name><name><surname>Balas</surname><given-names>E</given-names></name></person-group><article-title>Healthcare via cell phones: a systematic review</article-title><source>Telemed J E Health</source><year>2009</year><volume>15</volume><fpage>231</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1089/tmj.2008.0099</pub-id><pub-id pub-id-type="pmid">19382860</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fjeldsoe</surname><given-names>BS</given-names></name><name><surname>Marshall</surname><given-names>AL</given-names></name><name><surname>Miller</surname><given-names>YD</given-names></name></person-group><article-title>Behavior change interventions delivered by mobile phone telephone short-message service</article-title><source>Am J Prev Med</source><year>2009</year><volume>36</volume><issue>2</issue><fpage>165</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.amepre.2008.09.040</pub-id><pub-id pub-id-type="pmid">19135907</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Maddison R, Pfaeffli L, Whittaker R, Stewart R, Kerr A, Jiang Y, Rawstorn J, Carter K, Whittaker R. The HEART mobile phone trial: the partial mediating effects of self-efficacy on physical activity among cardiac patients. Front Public Health. 2014;2:27. 10.3389/fpubh.2014.00056.</mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Maddison R, Pfaeffli L, Whittaker R, Stewart R, Kerr AJ, Jiang A, Kira G, Leung W, Dalleck L, Carter KH, et al. A mobile phone intervention increases physical activity in people with cardiovascular disease: results from the HEART randomised controlled trial. Eur J Prev Cardiol. 2014. 10.1177/2047487314535076.</mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Chow C, Redfern J, Hillis G, Thakkar J, Santo K, Hackett ML, Jan S, Graves N, de Keizer L, Barry T, et al. Effect of lifestyle-focused text messaging on risk factor modification in patients with coronary heart disease: a randomized clinical trial. J Am Med Assoc. 2015;314(12):1255–66. 10.1001/jama.2015.10945.</mixed-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfaeffli Dale</surname><given-names>L</given-names></name><name><surname>Whitatker</surname><given-names>R</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Stewart</surname><given-names>R</given-names></name><name><surname>Rolleston</surname><given-names>A</given-names></name><name><surname>Maddison</surname><given-names>R</given-names></name></person-group><article-title>Improving coronary heart disease self-management using mobile technologies (Text4Heart): a randomised controlled trial protocol</article-title><source>Trials</source><year>2014</year><volume>15</volume><fpage>71</fpage><pub-id pub-id-type="doi">10.1186/1745-6215-15-71</pub-id><pub-id pub-id-type="pmid">24588893</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Dale L, Whittaker R, Jiang Y, Stewart R, Rolleston A, Maddison R. Text message and internet support for coronary heart disease self-management: results from the Text4Heart randomized controlled trial. J Med Internet Res. 2015;17(10):e237. 10.2196/jmir.4944.</mixed-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glasgow</surname><given-names>R</given-names></name><name><surname>McKay</surname><given-names>H</given-names></name><name><surname>Piette</surname><given-names>J</given-names></name><name><surname>Reynolds</surname><given-names>K</given-names></name></person-group><article-title>The RE-AIM Framework for evaluating interventions: what can it tell us about approaches to chronic illness management?</article-title><source>Patient Educ Couns</source><year>2001</year><volume>44</volume><fpage>119</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/S0738-3991(00)00186-5</pub-id><pub-id pub-id-type="pmid">11479052</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Chan A, Tetzlaff J, Altman D, Laupacis A, Gøtzsche P, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200-207. 10.7326/0003-4819-158-3-201302050-00583.</mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Eysenbach G, CONSORT-EHEALTH Group. CONSORT-EHEALTH: improving and standardizing evaluation reports of web-based and mobile health interventions. J Med Internet Res. 2011;13:e126. 10.2196/jmir.1923.</mixed-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerr</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>M</given-names></name><name><surname>White</surname><given-names>H</given-names></name><name><surname>Doughty</surname><given-names>R</given-names></name><name><surname>Nunn</surname><given-names>C</given-names></name><name><surname>Devlin</surname><given-names>G</given-names></name><name><surname>Grey</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Flynn</surname><given-names>C</given-names></name><name><surname>Rhodes</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>The All New Zealand Acute Coronary Syndrome Quality Improvement Programme: implementation, methodology and cohorts (ANZACS-QI 9)</article-title><source>N Z Med J</source><year>2016</year><volume>5</volume><issue>129</issue><fpage>23</fpage><lpage>36</lpage></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerr</surname><given-names>AJ</given-names></name><name><surname>McLachlan</surname><given-names>A</given-names></name><name><surname>Furness</surname><given-names>S</given-names></name><name><surname>Broad</surname><given-names>J</given-names></name><name><surname>Riddell</surname><given-names>T</given-names></name><name><surname>Jackson</surname><given-names>R</given-names></name><name><surname>Wells</surname><given-names>S</given-names></name></person-group><article-title>The burden of modifiable cardiovascular risk factors in the coronary care unit by age, ethnicity, and socioeconomic status—PREDICT CVD-9</article-title><source>N Z Med J</source><year>2008</year><volume>121</volume><issue>1285</issue><fpage>20</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">19079434</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Thornley S, Marshall R, Chan WC, Kerr AJ, Harrison J, Jackson G, Crengle S, Wright C, Wells S, Jackson R. Four out of ten patients are not taking statins regularly during the 12 months after an acute coronary event. Eur J Cardiovasc Prev Rehabil. 2011;19(3):349-57. 10.1177/1741826711403069.</mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Pfaeffli Dale L, Whittaker R, Eyles H, Ni Mhurchu C, Ball K, Smith N, Maddison R. Cardiovascular disease self-management: pilot testing of an mHealth eating program. Pers Med. 2014;4:88–101. 10.3390/jpm4010088.</mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Bramley D, Riddell T, Whittaker R, Corbett T, Lin R-B, Wills M, Jones M, Rodgers A. Smoking cessation using mobile phone text messaging is as effective in Maori as non-Maori. N Z Med J. 2005;118(1216):74-83. <ext-link ext-link-type="uri" xlink:href="http://www.nzma.org.nz/journal/118-1216/1494/">http://www.nzma.org.nz/journal/118-1216/1494/</ext-link>.</mixed-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodgers</surname><given-names>A</given-names></name><name><surname>Corbett</surname><given-names>T</given-names></name><name><surname>Bramley</surname><given-names>D</given-names></name><name><surname>Riddell</surname><given-names>T</given-names></name><name><surname>Wills</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>R-B</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name></person-group><article-title>Do u smoke after txt? Results of a randomised trial of smoking cessation using mobile phone text messaging</article-title><source>Tob Control</source><year>2005</year><volume>14</volume><issue>4</issue><fpage>255</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1136/tc.2005.011577</pub-id><pub-id pub-id-type="pmid">16046689</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Free</surname><given-names>C</given-names></name><name><surname>Knight</surname><given-names>R</given-names></name><name><surname>Robertson</surname><given-names>S</given-names></name><name><surname>Whittaker</surname><given-names>R</given-names></name><name><surname>Edwards</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Rodgers</surname><given-names>A</given-names></name><name><surname>Cairns</surname><given-names>J</given-names></name><name><surname>Kenward</surname><given-names>M</given-names></name><name><surname>Roberts</surname><given-names>I</given-names></name></person-group><article-title>Smoking cessation support delivered via mobile phone text messaging (txt2stop): a single-blind, randomised trial</article-title><source>Lancet</source><year>2011</year><volume>378</volume><issue>9785</issue><fpage>49</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(11)60701-0</pub-id><pub-id pub-id-type="pmid">21722952</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">Leventhal H, Meyer D, Nerenz DR. The common sense representation of illness danger. In: Rachman S, editor. Contributions to Medical Psychology. New York: Pergamon; 1980. p. 7–30.</mixed-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandura</surname><given-names>A</given-names></name></person-group><article-title>Human agency in social cognitive theory</article-title><source>Am Psychol</source><year>1989</year><volume>44</volume><fpage>1175</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1037/0003-066X.44.9.1175</pub-id><pub-id pub-id-type="pmid">2782727</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Broadbent E, Ellis CJ, Thomas J, Gamble G, Petrie KJ. Further development of an illness perception intervention for myocardial infarction patients: a randomised controlled trial. J Psychosom Res. 2009;67(1):17–23.</mixed-citation></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">New Zealand Guidelines Group: Best Practice Evidence-based Guideline: The Assessment and Management of Cardiovascular Risk. Wellington, New Zealand: New Zealand Guidelines Group; 2003.</mixed-citation></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">Morisky D, Ang A, Krousel-Wood M, Ward H. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008;10(5):348–54.</mixed-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaw</surname><given-names>K</given-names></name><name><surname>Wareham</surname><given-names>N</given-names></name><name><surname>Bingham</surname><given-names>S</given-names></name><name><surname>Welsch</surname><given-names>A</given-names></name><name><surname>Luben</surname><given-names>R</given-names></name><name><surname>Day</surname><given-names>N</given-names></name></person-group><article-title>Combined impact of health behaviours and mortality in men and women: The EPIC-Norfolk Prospective Population Study</article-title><source>PLoS Med</source><year>2008</year><volume>5</volume><issue>1</issue><fpage>e12</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.0050012</pub-id><pub-id pub-id-type="pmid">18184033</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="other">Maddison R, Roberts V, Bullen C, McRobbie H, Jiang Y, Prapavessis H, Glover M, Taylor S, Brown P. Design and conduct of a pragmatic randomized controlled trial to enhance smoking-cessation outcomes with exercise: The Fit2Quit study. Ment Health and Phys Act. 2010;3(2):92–101. 10.1016/j.mhpa.2010.09.003.</mixed-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godin</surname><given-names>G</given-names></name><name><surname>Shephard</surname><given-names>RJ</given-names></name></person-group><article-title>A simple method to assess exercise behavior in the community</article-title><source>Can J Appl Sport Sci</source><year>1985</year><volume>10</volume><issue>3</issue><fpage>141</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">4053261</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bush</surname><given-names>K</given-names></name><name><surname>Kivlahan</surname><given-names>DR</given-names></name><name><surname>McDonell</surname><given-names>MB</given-names></name><name><surname>Fihn</surname><given-names>SD</given-names></name><name><surname>Bradley</surname><given-names>KA</given-names></name></person-group><article-title>The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test</article-title><source>Arch Intern Med</source><year>1998</year><volume>158</volume><issue>16</issue><fpage>1789</fpage><lpage>1795</lpage><pub-id pub-id-type="doi">10.1001/archinte.158.16.1789</pub-id><pub-id pub-id-type="pmid">9738608</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Ministry of Health</collab></person-group><source>New Zealand Health Survey 2006/07 Adult Questionnaire</source><year>2008</year><publisher-loc>Wellington</publisher-loc><publisher-name>Ministry of Health</publisher-name></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glasgow</surname><given-names>R</given-names></name><name><surname>Klesges</surname><given-names>L</given-names></name><name><surname>Dzewaltowski</surname><given-names>D</given-names></name><name><surname>Estabrooks</surname><given-names>P</given-names></name><name><surname>Vogt</surname><given-names>T</given-names></name></person-group><article-title>Evaluating the impact of health promotion programs: using the RE-AIM framework to form summary measures for decision making involving complex issues</article-title><source>Health Educ Res</source><year>2006</year><volume>21</volume><issue>5</issue><fpage>688</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1093/her/cyl081</pub-id><pub-id pub-id-type="pmid">16945984</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>K</given-names></name><name><surname>Zoellner</surname><given-names>J</given-names></name><name><surname>Motley</surname><given-names>M</given-names></name><name><surname>Estabrooks</surname><given-names>PA</given-names></name></person-group><article-title>Understanding the internal and external validity of health literacy interventions: a systematic literature review using the RE-AIM framework</article-title><source>J Health Commun</source><year>2011</year><volume>16</volume><issue>3</issue><fpage>55</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1080/10810730.2011.604381</pub-id><pub-id pub-id-type="pmid">21951243</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="other">Estabrooks P, Fisher E, Hayman L. What is needed to reverse the trends in childhood obesity? A call to action. Ann Behav Med. 2008;36(3):209–16. 10.1007/s12160-008-9070-7</mixed-citation></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="other">Klesges L, Estabrooks P, Dzewaltowski D, Bull S, Glasgow R. Beginning with the application in mind: designing and planning health behavior change interventions to enhance dissemination. Ann Behav Med. 2005;29(2):66–75. 10.1207/s15324796abm2902s_10.</mixed-citation></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="other">Estabrooks PA, Glasgow RE. Translating effective clinic-based physical activity interventions into practice. Am J Prev Med. 2006;31(4):S45–56. 10.1016/j.amepre.2006.06.019.</mixed-citation></ref><ref id="CR59"><label>59.</label><mixed-citation publication-type="other">Evans B, Snooks H, Howson H, Davies M. How hard can it be to include research evidence and evaluation in local health policy implementation? Results from a mixed methods study. Implement Sci. 2013;8(17). 10.1186/1748-5908-8-17.</mixed-citation></ref><ref id="CR60"><label>60.</label><mixed-citation publication-type="other">Glasgow RE: What does it mean to be pragmatic? Pragmatic methods, measures, and models to facilitate research translation. Health Educ Behav. 2013;40(3):257–65. 10.1177/1090198113486805.</mixed-citation></ref><ref id="CR61"><label>61.</label><mixed-citation publication-type="other">Kessler R, Purcell E, Glasgow RE, Klesges L, Benkeser RM, Peek C. What does it mean to employ the RE-AIM model? Eval Health Prof. 2012;36(1):44–66. 10.1177/0163278712446066.</mixed-citation></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other">Estabrooks P, Shoup JA, Gattshall M, Dandamudi P, Shetterly S, Xu S. Automated telephone counseling for parents of overweight children: a randomized controlled trial. Am J Prev Med. 2009;36:35–42. 10.1016/j.amepre.2008.09.024.</mixed-citation></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">Pinard C, Hart M, Hodgkins Y, Serrano E, McFerren M, Estabrooks P. Smart choices for healthy families: a pilot study for the treatment of childhood obesity in low-income families. Health Educ Behav. 2012;39(4):433–45.</mixed-citation></ref><ref id="CR64"><label>64.</label><mixed-citation publication-type="other">Estabrooks P, Smith-Ray R, Dzewaltowski D, Dowdy D, Lattimore D, Rheaume C, Ory M, Bazzarre T, Griffin S, Wilcox S: Sustainability of evidence-based community-based physical activity programs for older adults: lessons from Active for Life. Translational Behavioral Medicine 2011;1(2):208–15. 10.1007/s13142-011-0039-x.</mixed-citation></ref><ref id="CR65"><label>65.</label><mixed-citation publication-type="other">Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. American Journal of Public Health 1999;89(9):1322–27.</mixed-citation></ref><ref id="CR66"><label>66.</label><mixed-citation publication-type="other">Glasgow RE, Askew S, Purcell P, Levine E, Warner ET, Strange KC, Colditz GA, Bennett GG: Use of REAIM to address health inequalities: Application in a low-income community health centre-based weight loss and hypertension self-managment program. Translational Behavioral Medicine 2013;3(2):200–10.</mixed-citation></ref><ref id="CR67"><label>67.</label><mixed-citation publication-type="other">Kaplan R, Stone A. Bringing the laboratory and clinic to the community: mobile technologies for health promotion and disease prevention. Annu Rev Psychol. 2013;64:471–98. 10.1146/annurevpsych-113011-143736.</mixed-citation></ref></ref-list></back></article>